BioCentury
ARTICLE | Clinical News

MYK-461: Phase I data

July 18, 2016 7:00 AM UTC

Top-line data from the open-label, U.S. Phase I MYK-461-001 trial in 15 patients with HCM showed that a single 144 mg dose of MYK-461 led to 1 serious adverse event of vasovagal reaction that spontane...